GlassScriptPhysician profile
Michael A Giuliano
NPI 1295850063
$1,059.97
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $29.78 · 2021: $13.30 · 2022: $141 · 2023: $368 · 2024: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $667.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $405.43 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $274.93 | 2023-2024 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $97.62 | 2022 | |
| Sunovion Pharmaceuticals INC. | $85.25 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.35 | 2019 | |
| Lundbeck LLC | $41.05 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $30.20 | 2022 | |
| Vertical Pharmaceuticals, LLC | $14.93 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.92 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.72 | 2019 | |
| Alfasigma USA, INC. | $13.30 | 2021 | |
| Glaxosmithkline, LLC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Giuliano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.